About Humane Genomics | Engineering Precision Oncolytic Virus Therapies

Why Our Viral Therapies Stand Out

We began by asking the question: What are the most important characteristics of an OVT? And then we designed our therapies to have these characteristics.

• Unparalleled Safety. By employing both selective infection and selective replication, we ensure that our therapies target only cancer cells.
• Highly Lytic. We use RNA viruses, which are highly lytic to ensure efficient killing of cancer cells.
• Predictive Translation. We prioritize models that translate from in vitro to in vivo and ultimately to human applications.
• Maximized Therapeutic Duration. By engineering low immunogenicity, therapies can persist without premature neutralization.
• Systemic Delivery. Designed for systemic administration to improve odds of addressing present metastasis.
• Cost-Effective Production. Highly replicative viruses can be potent and efficient to manufacture.

Our Cutting-Edge Platform

Engineering RNA viruses efficiently remains challenging, even with today’s technology. We pride ourselves on our state-of-the-art platform, developed to expedite the design and testing of our oncolytic viruses.

Here’s how it works:

Computer-Aided Design

• Utilization of validated building blocks from our library and new ones from literature.
• The freedom to design—changing base pairs or whole genes, tailored to specific needs.
• Codon optimization to tune replication speed as needed.
• Optimization for synthesis, followed by assembly using synthetic DNA.

DNA Synthesis

• Sequence-perfect DNA, paving the way for a high-quality pipeline.
• Rapid improvements enabling longer fragments, larger quantities, and reduced cost.

Making the genome and rescuing the virus

• Assemble synthesized fragments to form the complete viral genome.
• Cells are transfected, leading to virus production and efficacy testing. ( Read more)

The Power of Vesicular Stomatitis Virus

Our therapies are based on Vesicular Stomatitis Virus (VSV) due to its advantages:

• Ease of retargeting by changing the glycoprotein.
• Highly lytic nature for fast and effective killing of cancer cells.
• Linear genome simplifies engineering.
• Well-researched with extensive published work.
• Low seroprevalence helps reduce premature neutralization risk.

Our publications

For reference, here is a list of our publications in chronological order.

1. Chad M. Moles, Rupsa Basu, Peter Weijmarshausen, Brenda Ho, Manal Farhat, Bruce Smith et al. 2024
   Leveraging Synthetic Virology for the Rapid Engineering of Vesicular Stomatitis Virus (VSV)
   Viruses • Published
   Abstract PDF

2. Chad M. Moles, Rupsa Basu, Peter Weijmarshausen, Brenda Ho, Manal Farhat, Bruce Smith et al. 2024
   Oncolytic virus therapy with two-factor authentication shows robust safety and efficacy in liver cancer
   AACR • Published
   Abstract

3. Rupsa Basu, Chad M. Moles et al. 2023
   Rational selection of an ideal oncolytic virus to address current limitations in clinical translation
   International Review of Cell and Molecular Biology / Elsevier • Published
   Abstract

4. Chad Moles, Rupsa Basu, Taylor Flaat, Christopher Collado, Peter Weijmarshausen et al. 2023
   Oncolytic VSV with retargeted glycoprotein and genetic ON switch for precise targeting of liver cancer using a synthetic virology platform
   AACR • Published
   Abstract